Background: Current dosing of intrapleural fibrinolytic therapy (IPFT) in adults with complicated parapneumonic effusion (CPE) / empyema is empiric, as dose-escalation trials have not previously been conducted. We hypothesized that LTI-01 (scuPA), which is relatively resistant to PA inhibitor-1 (PAI-1), would be well-tolerated.
Introduction
Complicated parapneumonic pleural effusions (CPE) or empyema with failed drainage and pleural sepsis are dire consequences of pleural infection and remain important clinical challenges. Serious pleural infections are reported to occur in about 90,000 patients annually in the US(1), are increasing in frequency in adults (2) and children (3) and are associated with a mortality rate of up to 20 percent(4). Patients often have hospital stays exceeding hospital Diagnosis Related Group (DRG)-payments to hospitals in the US and can require surgery to relieve pleural sepsis (5) . Treatment entails costs of care of more than a third of a billion dollars in the US and UK (5, 6) , indicative of a substantive global burden.
Intrapleural fibrinolytic therapy (IPFT) has been part of the therapeutic arsenal for CPE/empyema for over sixty years, predicated on the concept that lysis of the intrapleural, extravascular fibrinous neomatrix can pharmacologically relieve impaired drainage of purulent collections that support persistent pleural sepsis (7) . While generally effective in children, the safety profile and efficacy of IPFT in adult patients currently remains unclear (8) (9) (10) . A number of unapproved agents have been used to augment pleural drainage in adults with CPE/empyema, with variable results (11, 12) .
We used single chain urokinase plasminogen activator; scuPA, as the interventional agent and tested its safety after intrapleural delivery as the primary study objective. LTI-01, a new form of scuPA produced in Chinese Hamster Ovary (CHO) cells, is an IPFT candidate which offers a number of conceptual advantages including relative resistance to inhibition by plasminogen activator inhibitor-1 (PAI-1), the major plasminogen activator (PA) inhibitor within pleural fluids (PFs) (13) and durable, low grade bioavailability in PFs over 24h (13) . Extensive analyses including Good Laboratory Practice (GLP)-toxicology studies performed as part of NHLBI SMARTT (Science Moving Towards Translation and Therapy) contract # HHSN268201100014C demonstrated that this was a well-tolerated agent, including after intrapleural administration. In extensive preclinical testing, scuPA IPFT effectively cleared fibrinous collections associated with several forms of pleural injury including empyema (13) (14) (15) (16) (17) (18) .
A major impediment to interpretation of all trials concerning the efficacy and safety of IPFT to date has been that the dosing of IPFT has been empiric, with dosing of all forms of IPFT subject to arbitrary rather than evidence-based selection (19, 20) . We are unaware of any previous phase 1; dose-escalation, trials done to establish dosing and safety as a prelude to efficacy testing in the IPFT field. Further, we are unaware of any prior reports in which PF bioactivity or processing of any of the IPFT agents was examined.
Such analyses were not included in the design of the large and influential MIST1 and 2 phase 2 studies (4, 5) . In the present report, we sought to address these critical gaps in two ways. First, we conducted the first in-field dose-escalation trial of any intrapleural fibrinolysin and tested intrapleural recombinant LTI-01 in patients with pre-hoc CPE/empyema, pleural loculation and failure to drain. Second, we integrated first-in-kind comprehensive analyses of the intrapleural and systemic processing of LTI-01 into the protocol design. These analyses enabled us to assess the safety and PF bioactivity of dose-escalated LTI-01 IPFT in adult CPR/empyema subjects and to better understand its contribution to treatment outcomes better.
Results
Demographics. The Intent To Treat (ITT) population comprised all subjects (n=14) who enrolled in the study and supplied post-screening data. The ITT population was used for summaries of all disposition, demographic and other baseline data. The demographics of the ITT population are illustrated in Table 1 . All 14 subjects received antibiotics prior to and at screening. After study entry, they were continued on the regimens listed in Supplement Table 1 , which also describes the pleural fluid characteristics, biomarkers and cultures. PF cultures were positive for 4/14 patients at study entry, one was not cultured, and 9 yielded no growth. Three of the four PF positive cultures yielded Streptococcal species. Blood cultures were negative in all patients. All subjects had purulent PF, Gram stain or culture positive or pH ≤7.2, and had loculated PF by chest imaging with failure to drain over 3h of initial observation (Figure 1 ).
Safety Results
Bleeding Events. No acute intrapleural or systemic bleeding events were observed in any of the LTI-01-treated subjects. There were likewise no consistent effects on heart rate, blood pressure, respiratory rate or temperature at all dose levels. Fever (>37.4 0 C) was present in only 1 patient.
Treatment-emergent adverse events (TEAEs).
Assessments were done according to the study schedule (Supplement, Table 2 and Study Protocol). A total of 22 TEAEs were recorded in 7 (50.0%) of the14 subjects (Table 2) . No TEAE was considered to be related to study treatment, based on treating physician assessment. TEAEs did not increase with dose level, as 10 were recorded in the low dose group (50,000 IU), compared to no such events in the high dose group (800,000 IU). The most frequently occurring TEAEs were hypotension and post-procedural persistent drain fluid (3 events each), and pleuritic pain (2 subjects each). Three TEAEs occurring during active study participation were classified as severe including metastatic squamous cell carcinoma, sinus tachycardia, lung abscess, and 11 were classified as moderate. There were two further TEAEs of note, neither attributed to LTI-01. One subject (200,000 IU) had a post-procedural hematoma pre-dose on Day 3. That was considered unlikely to be related to study drug by the local investigator and thought to be related to drain insertion. The other (50,000 IU) had sinus tachycardia. There were no life-threatening TEAEs and none led to study discontinuation.
SAEs. Serious Adverse Events (SAEs) were collected from the time of first study dose to Day 28, hospital discharge or death, whichever came first (Supplement, Table 3 ). Two subjects experienced SAEs, both leading to death, with neither death attributed to administration of LTI-01. One subject (50,000 IU)
with clinical empyema and failure to drain at enrollment died from metastatic squamous cell carcinoma on Day 20. This subject had the condition in addition to CPE, given that malignant cells were found in his PF after entry. A second subject (400,000 IU) has a ruptured lung abscess and died of a contralateral pneumonia on Day 86. This subject had a cavitating lung lesion of the right lower lobe, pneumonia, empyema and obstruction of his bronchus intermedius as well as bile duct obstruction at entry. No additional SAEs occurred after Day 28 or after discharge as of database lock (10 May, 2018) . No protocol deviations were considered to affect study objectives or the integrity of the data (Supplement, Section 1).
Treatment compliance. Six of the 14 subjects did not receive dosing on Day 3. In accord with the protocol, second or third LTI-01 doses could be withheld if complete resolution of the pleural process occurred after the prior dose. In one patient in the 50,000 IU group, treatment was stopped after two doses of LTI-01 after which tPA, or tPA/DNase was administered on days 3-5 by the treatment team. In a subject in the 100,000 IU group, LTI-01 was not given on day 3 because of an elevated PT of 16 sec. This subject received tPA/DNase on days 5-8 because of an increased leukocyte count and increased CRP.
Another patient in this group did not receive the third dose of LTI-01 because of chest tube migration and required no further therapy. The subject in the 200,000 IU group with a chest wall hematoma did not receive the third dose because of clinical improvement following LTI-01 IPFT. In a patient in the 800,000
IU group it was felt that a third dose was likewise not warranted because of radiographic/clinical improvement. In the other subject in this group, a partial third dose was given because of chest tube blockage and the patient required no further IPFT.
Clinical laboratory testing.
Mean hemoglobin decreased at all time points for the pooled subject population, while total leukocyte and neutrophil counts generally decreased during and after LTI-01 IPFT Plasma fibrinogen never fell below the top normal lab range levels in any subject, indicating no evidence of systemic fibrinogenolysis (Supplement, Figure S4 ). There were no changes in blood chemistries attributable to LTI-01 IPFT (not shown).
Preliminary Assessments of Efficacy. No subject was referred to surgery. None experienced a lifethreatening event prior to discharge. All but one subject with underlying pleural malignancy identified after entry had a relative decrease in pleural density area or volume during the study ( Figure S5 ). Pharmacokinetic (PK), pharmacodynamic (PD) analyses, and intrapleural processing of LTI-01. uPArelated antigen (labeled as urokinase) data are provided in the Supplement, Table 4 . PF uPA antigen levels ( Figure 2A ; PD) at 3 h after delivery were markedly elevated, when compared to pre-injection levels (p<0.05). They ranged from a mean Day 1 postdose (3 hour) level of 376,830 pg/mL in the 50,000 IU dose group compared to 2,129,776 pg/mL in the 800,000 IU dose group (Figure 2A ). The level of the uPA antigen at 23 h (Day 2 pre-dose) was also higher (p<0.05) than that before treatment (Day 1 pre-dose).
There was no statistically significant difference (p>0.05) between PF uPA antigen levels on day 1, 2 or 3 at 3 h after treatment. These results reflect successful delivery of the LTI-01 to the pleural space, maximal detectable levels at 3 h and retention of the elevated uPA antigen up to 23 h. Plasminogen activating (PA) and fibrinolytic activities were next determined in all PF samples. As expected, changes in the PF PA activity with time ( Figure 2B ) paralleled those observed for uPA antigen ( Figure 2A ). While PA activity was relatively high at 3 h post treatment, it was at or below the limit of detection at baseline and at 23 h after IPFT ( Figure 2B ). Notably, PF fibrinolytic activity was also relatively high at 3 h after IPFT and suppressed at the baseline and 23 h ( Figure 2C ). PF levels of fibrin degradation products (D-dimers) ( Figure 2D) increased at 3 h post treatment and temporally correlated with changes in fibrinolytic activity. These results confirm bioavailability of LTI-01 in PFs of treated patients with conversion into mature two-chain enzyme, activation of endogenous plasminogen (Supplement Figure S6) , and generation of durable fibrinolytic activity, with an increase in PF D-Dimers; the products of fibrinolysis in PFs. Plasminogen levels were unchanged in plasma.
Effects of LTI-01 on changes of the fibrinolytic system in plasma. In contrast to PF (Figure 2A ), plasma uPA-related antigen levels (PK) did not significantly increase after dosing on Day 1 at 3-hour post-dose compared with pre-dose ( Figure 2E ) or at other dosing intervals. The largest increase was seen in one of the subjects dosed at 800,000 IU with an increase of approximately 700 pg/mL post-dose (1446 pg/mL) compared to the pre-dose level (743 pg/mL). Notably, uPA antigen levels in plasma ( Figure 2E ) were almost three orders of magnitude lower than those in PF at 3 h post-treatment ( Figure 2A ). Moreover, while the level of uPA antigen in the PF changed with time, uPA in the circulation remained stable ( Figure   2E ). Similar to uPA, the levels of D-dimers in plasma ( Figure 2F ) were up to three orders of magnitude lower than those in PF ( Figure 2D ). Plasma D-dimers did not change (p>0.05) during the 3-day treatment period ( Figure 2F ), Indicating no significant systemic changes in fibrinolytic activity.
Endogenous inhibitors affect LTI-01 and intrapleural fibrinolysis. Intrapleural concentrations of active
PAI-1 in all pre-treatment samples were elevated (160-200 ng/ml; Figure 3A ) resulting in the observed inhibition of the plasminogen activation ( Figure 2B ) and fibrinolysis ( Figure 2C ). On the other hand, the level of active PAI-1 in the majority of PF samples collected at 3 h post treatment with LTI-01 was at or below the limit of detection ( Figure 3A ; p<0.01 versus baseline levels). Thus, PAI-1 activity at 3 h was completely inhibited by PF LTI-01, which promotes its conversion to two-chain uPA to activate endogenous plasminogen and thus support intrapleural fibrinolysis. Interestingly, four samples with elevated PAI-1 activity detected at 3 h (one at Days 1 and 3 and two at Day 2; Figure 3A ; post) possessed no PA activity. Thus, an increase in the active PAI-1 at 3 h likely indicates either incomplete delivery of IPFT or fast in vivo inactivation of LTI-01 in PFs of these particular patients. PAI-1 total antigen was also significantly increased in PFs ( Figure 3B ) versus levels found in the plasma (not shown), reflecting overexpression of local PAI-1 in infectious pleural injury. The increase in the PF levels of uPA antigen at 23 h, when compared to the baseline ( Figure 2A ) without a significant increase in PA activity (Figure 2B) is consistent with formation of bioactive complexes with alpha2--macroglobulin (A2M), as observed in pre-clinical models of pleural injury (13) . Indeed, levels of intrapleural A2M/uPA complexes ( Figure 3C) increased at 3 h after IPFT and decreased at 23 h post-treatment. Next, we tested the concept of Fibrinolytic Potential (FP) as a personalized predictor of the response to LTI-01 IPFT (21, 22) .
Supplementation of the pre-dose (baseline and at 23h) PFs with two chain uPA (the FP) generated robust levels of fibrinolytic activity (median 0.7-1.3 AU; p<0.01 versus unsupplemented baseline levels). We evaluated PF samples collected prior to treatment and correlated the FP to changes in the pleural density area, as assessed by CXR. There was a significant correlation between the FP (Figure 3D ; n=8; r= -0.79, p<0.05) with the % relative change of CXR pleural density area post-treatment (Table 3 and panel A).
Individualized assessments of derangements of PF components of the fibrinolytic system and outcomes of LTI-01 IPFT. First, we analyzed the findings in subjects with clinical improvement proximate to LTI-01 administration without any switch to another form of IPFT or referral to surgery and reduced pleural opacification by either CXR or chest CT imaging. One patient in the 400,000IU group; 102-1005, received all three doses and temporally responded with clinical resolution of pleural sepsis and a relative reduction of pleural density of 45%. Interestingly, this patient demonstrated the highest levels of uPA antigen; >100 µg/ml, in post-treatment pleural fluids as well as the lowest levels of PAI-1 PF concentrations. In another patient in the 800,000IU group; 102-1007, clinical resolution of pleural sepsis was achieved with a relative reduction in the pleural density of 36%, so that a third dose of LTI-01 was not administered. This patient had elevated levels of PF uPA >100 µg/ml with low levels of PF PAI-1 compared to other subjects (Supplement, Figure 7 A, B). In the other patient receiving 800,000 IU, only a portion of the third dose was delivered attributable to chest tube obstruction and pleural sepsis likewise resolved without further IPFT or a referral to surgery and PF PAI-1 levels remained low at days 1 and 2 post-dosing. One additional patient; 102-1001, treated with 50,000 IU/ml drained effectively with a relative reduction of pleural density of 85% by chest X-ray, had relatively very low levels of PF PAI-1 with concurrent increments of uPA and resolution of clinical pleural sepsis upon completion of LTI-01 dosing (Supplement, Figure 7A and B).
Other patients with poor outcomes remote to the treatment period had relatively elevated levels of PAI-1 or did not complete therapy while those that responded clinically and radiographically typically had evidence of appropriate drug delivery with elevated PF uPA and reduced PAI-1 activity, as described in detail for all other subjects (n=10) in the Supplement, Section 2 and Figure S7 .
Discussion
Since the inception of IPFT (7, 23) , a number of fibrinolysins, which activate plasminogen to form plasmin and lyse fibrin, have been used to treat adults with CPE/empyema (19, 24) . In previous metaanalyses, it was concluded that there was equivocal evidence supporting the use of IPFT for these patients (8, 9) , with a more recent study unable to assess the impact of IPFT (10) . Among factors contributing to the uncertainty, IPFT dosing remains empiric and bioactivity of currently used IPFT agents was not confirmed in prior clinical trial testing in adults with empyema/CPE (19, 20, 25) .
In addition, to our knowledge, no form of IPFT has been approved by any regulatory agency in the US, UK or elsewhere to date. A major initial requirement for such approval is the performance of phase 1 testing in humans to establish safety. We manufactured a highly purified recombinant active pharmaceutical form of scuPA to meet requirements for regulatory approval. Initial dosing for this trial was established with GLP toxicologic studies. The drug product; LTI-01, was used in what we believe to be the first dose-escalation safety trial with CPE/empyema.
The premise for testing LTI-01 is based upon its favorable biochemical properties and unique processing in PFs. Over the past twenty years, our group published several preclinical studies suggesting that scuPA was effective and well-tolerated in organizing pleural injury, as reviewed recently (20) . First, scuPA was found to be well-tolerated and in tetracycline-induced pleural injury and empyema in rabbits and cleared pleural collections without causing intrapleural or systemic bleeding (13) (14) (15) (16) . Secondly, scuPA
IPFT is relatively PAI-1 resistant in PFs (13) . This issue is of particular importance, given the characteristically high levels of PAI-1 that occur within empyema/CPE PFs (15, 26, 27) and as confirmed in this study. While other inhibitors, including antiplasmins are present in CPE/empyema PFs, increased pleural organization associated with PAI-1 overexpression(17) attests to its impact on outcomes. We found that levels of total and active PF PAI-1 are variably increased in patients with CPE/empyema, which implies that current empiric selection of IPFT could predispose to bleeding in some patients with relatively low PF PAI-1 or be insufficient in those with high PAI-1. This variability also may explain why LTI-01 IPFT was effective over a range of doses in individual subjects with different levels of PF PAI-1.
The demographic profile of the subjects reflects the variety of causes of pleural infection that may lead to loculation and failed pleural drainage. Subjects had a mean age of about 65 years, comparable to the cohorts previously enrolled in the MIST1 and 2 trials (4, 5) . A limitation of the study is that only 14 of the 21 subjects that could have been enrolled actually participated and there was no expansion of any of the cohorts as allowed by the protocol design (Supplement, Study Protocol).
Two consecutive patients who received the highest dose of 800,000 IU tolerated the drug well and required only two doses to relieve the pleural collection. Two (2) subjects died during the follow-up period after active study participation. Neither death was attributed to LTI-01 by the local investigator.
The maximal tolerated dose (MTD) of LTI-01 IPFT was not detected. However, the absence of safety signals offers a strong rationale for further dose escalations to identify the optimal dose to be tested in the next phase of development. Higher dose escalations were not included in the study design because of limited drug supply.
There were no bleeding events, either local or systemic in the study participants. This observation is of particular importance given reported bleeding rates of 5-28% associated with different forms of IPFT (28, 29) , despite some reports of lesser incidences (12, 30) . The absence of clinical bleeding was in keeping with our preclinical experience (11, 13, 14, 16, 18, 21, 31, 32) and pre-trial toxicology. The initial dose of 50,000 IU was felt to likely be subtherapeutic based on the literature (11, 33) . However, it was intentionally used to determine how well the study drug/vehicle/known impurities (Supplement, Protocol) were tolerated before escalating the dose. The exclusion criteria we used also had rigorous provisions designed to decrease bleeding risk associated with this trial (Supplement, Protocol). These included abnormalities of the screening coagulation profile, known platelet dysfunction or use of anti-platelet agents. Patients could receive deep vein thrombosis prophylaxis but not full anticoagulation, given reports of increased bleeding risk (34, 35) . Patients with a glomerular filtration rate of < 30 were also excluded. Plasma fibrinogen levels were screened, as levels below 100-150 mg/dL have been linked to bleeding risk in trauma patients (36) (37) (38) .
All patients maintained supraphysiologic levels of plasma fibrinogen, which is an acute phase reactant and plasma levels remained elevated throughout the treatment period. The data indicate that administration of LTI-01 IPFT was not associated with fibrinogenolysis and suggest that future screening for fibrinogen levels does not need to be routine in the adult CPE/empyema population. There was no consistent effect of LTI-01 IPFT on the coagulation profiles of treated subjects.
Reduced pleural opacification was generally observed by chest X-ray or chest CT imaging, using the methodology originally reported in the MIST2 trial(5). As a safety trial, this study was not powered to delineate efficacy. Therefore, this readout needs to be considered as encouraging but preliminary. PF drainage increased after LTI-01 IPFT but occurs with other forms of IPFT such as tPA/ DNase IPFT(5). All baseline assessments approximated the screening or Day 1 pre-dose period and post-treatment assessments approximated the day 4 post treatment interval, but some were obtained at later intervals, representing another confounder (Supplement). Nonetheless, LTI-01 IPFT was temporally associated with improved pleural opacification and concurrently improved the clinical status in four patients, including both subjects treated with 800,000 IU. These findings that support advancement to additional dose escalations/group expansion. Decreases in plasma CRP levels and in white cell and neutrophil counts that generally occurred in the subjects are consistent with improvement of the underlying pleural infections.
Lastly, the 4 subjects who received follow-up IPFT with tPA+/-DNase were all treated at one site and at the discretion of the treating team, which was permitted under the protocol.
To our knowledge, this is also the first study to assess the bioavailability and processing of IPFT in humans. PF analyses of uPA antigen (Figure 2A Figure   3A ), which inhibits PA activity ( Figure 2B ), and local generation of plasmin. Notably, the inhibition of the fibrinolysis at 23 h was independent of the dose of the LTI-01 or the day of the treatment. Moreover, the levels PF plasminogen and active PAI-1 observed at 23 h after the treatment were similar to those detected at the baseline ( Figure 3A) . Thus, at all pre-dosing intervals, plasminogen was sufficient to support plasmin generation by LTI-01 IPFT in PFs and confirmed by PF plasminogen levels (Supplement).
The correlation of the FP, a new companion diagnostic, with changes in opacification ( Figure 3D ) provides preliminary support for its application as a predictor of IPFT efficacy and justifies future testing of its ability to predict IPFT outcomes. The levels of PAI-1 antigen achieved in the PFs of patients in this study were comparable to those previously reported. (26, 39, 40) . Consistent with our more recent report (18) , PAI-1 activity was also markedly increased in these PFs. Increased levels of PF bioactive uPA-α2macroglubulin complexes at 3h after LTI-01 IPFT were generally identified ( Figure 3C ) and suggest that the mechanism of processing and bioavailability of LTI-01 IPFT used in these subjects was comparable to that of scuPA IPFT (Abbott Laboratories, glycosylated scuPA derived from S2 cells) used in our models of pleural injury and empyema (13, 18) .
The biochemical analyses we conducted allowed us to assess how individual responses to LTI-01
IPFT impacted outcomes These analyses helped us explain the efficacy of lower dosing of LTI-01 in some patients. The favorable results in the 800,000 IU-treated group are especially encouraging. We ultimately plan to advance this dose and conduct further dose escalations as a part of phase 2 testing. Ultimately, we hope to identify a dose of LTI-01 that is well-tolerated by patients with CPE/empyema and that can be effective in almost all patients, including those with high levels of PF PAI-1 activity.
In summary, this study offers several contributions that are novel to the field. LTI-01 was safe at the doses we tested. It was bioactive in CPE/empyema PFs. Analyses of the FP and processing of LTI-01
and perhaps other IPFT agents can inform understanding of treatment outcomes in individual subjects.
Treatment benefits observed in some subjects support the advancement of LTI-01 to further clinical trial testing. Selection of Doses in the Study. Dosing was first based on studies in models of intrapleural injury that demonstrated therapeutic benefit and tolerance and bioavailability of LTI-01 (13, 15, 16, 41) . We sought to initiate dosing at a level that was likely to be at or near a potentially therapeutic dose, since the study subjects had potentially life-threatening conditions. To balance this intention with a safe starting dose, a maximum recommended starting dose (MRSD) was calculated based on an assumption of an intrapleural no observed adverse effect level (NOAEL) of 0.25 mg/kg based on toxicology in rabbits and dogs, converting that dose to the human equivalent dose by allometrically scaling the dose based on body surface area and then adding a 10-fold safety factor to account for interspecies variation. This calculation resulted in an acceptable maximal safe starting dose of ~130,000 IU of LTI-01 for a 60 kg subject. To be conservative, we opted to initiate at a lower dose to assess potential effects of vehicle and impurities. The study protocol permitted completion of dosing after < 3 daily doses with complete resolution of the pleural process. Bleeding events were defined as an acute bleeding event with ≥2 g/dL drop in blood hemoglobin; development of melena, hemothorax or PF/blood hematocrit >50%.
Methods

Involved centers and Ethics
All subjects at all dose levels were observed for 4 days after last intrapleural LTI-01 treatment (or until hospital discharge if sooner). Clinical stability was to be documented before treatment of the next subject.
Blood and PF assessments included complete blood counts (CBC)s, coagulation and metabolic profiles, fibrinogen and CRP levels done before and at 3 and 23 h after dosing. Chest X-ray and CT scans and other safety assessments were also performed before and on at about 4 days after administration of LTI-01.
Blood Table 3 .
Efficacy endpoints of the study. Vital signs were monitored and referrals for surgery and mortality during hospitalization, radiographic improvement based on comparison of pre-treatment chest X-ray or CT scan to those done 23 ± 3 hours after the last received daily dose of LTI-01 IPFT, as previously reported(5). The first radiographic study was an upright 2-view chest X-ray. Pleural effusion was confirmed radiographically. If pleural loculation was suggested on the plain chest X-ray, it was confirmed using CT scanning of the chest or chest ultrasonography. CT scanning (high resolution if available) was done unless precluded by the clinical status of the subject or unavailability of the test. At 23 ± 3 hours after the third (or final) dose of LTI-01, PF related density was compared by follow-up chest X-ray, with relative change in pleural opacification versus baseline imaging, as previously described (5 Central Laboratory Analyses. These studies were done at UTHSCT and included D-dimer and PA as well as fibrinolytic activity levels in plasma and pleural fluids. Levels of PAI-1 antigen and activity levels were also assessed(18) as were levels of bioactive alpha 2-macroglobulin/uPA complexes (13) . The fibrinolytic potential (FP); measurement of fibrinolytic activity after supplementation of baseline PFs with two-chain uPA was determined in samples of PF collected prior to the IPFT as previously described (21, 22) . A total of n=8 PFs were available for these analyses.
Pharmacokinetics (PK) and pharmacodynamics (PD) analyses. These included total uPA antigen PK and PD in plasma and pleural fluids. A uPA ELISA; Quantikine ELISA (Urokinase, R&D Systems, DUPA00, Lot # 171962), was used to perform these studies. The assay measures uPA-related antigen and detects singlechain uPA, two-chain uPA, uPA-PAI-1 complexes, and uPA bound to its receptor (uPA-uPAR complexes).
Samples of PF and plasma were collected at the intervals stipulated, using methods appropriate for these assessments (Supplement, Table 4 ).
Prior and Concomitant Therapy. Subjects were expected to receive customary care including radiologic chest tube placement and initiation of antibiotics prior to enrollment. Radiologic tube placement, while not required, was considered justified as large bore tubes had not been proven to be more effective, were associated with greater morbidity, and radiologically placed tubes had the advantage of being located within the PF collection. Subjects could receive all other customary therapy for CPE/empyema. Antibiotic regimens used were at the discretion of the managing physician.
Subject Follow-up. At 3 and 12 months after treatment, attempts were made to document surgical referral, further hospitalization for CPE/empyema and mortality in treated subjects through the outpatient clinic.
Statistics. All statistical analyses were exploratory in nature with descriptive statistics (i.e. mean, standard deviation, median, maximum and minimum) provided for continuous variables. and A2M/uPA complexes (C) were determined. LTI-01 was delivered daily with doses 50 000 (pink symbols; n=3; 12 samples), 100 000 (blue symbols; n=3; 9 samples), 200 000 (orange symbols; n=3; 4 samples), 400 000 (purple symbols; n=3; 10 samples) and 800 000 (green symbols; n=2; 6 samples) IU per injection. Samples of pleural fluid (Day 1 pre-treatment n= 12, Day1 post-treatment n= 14, Day 2 pre-treatment n= 9, Day 2 post-treatment n= 13, Day 3 pretreatment n= 2, Day 3 post-treatment n= 8 and Day 4 n= 4) were collected daily (1-4 days) prior to each LTI-01 injection (pre) and 3 h after (past) treatment as described in the Materials and Methods section. Levels of PAI-1 antigen and PAI-1 activity were determined in pleural fluid (A) using ELISA (Molecular Innovations, MI). Levels of bioactive alpha 2-macroglobulin/uPA (A2M/uPA) (C) complexes were determined as described elsewhere (13) . Each point represents an average of at least two independent measurements. Data are presented as dot plots with horizontal lines indicating the medians and whiskers representing interquartile range; * P<0.05; ** P<0.001; *** P<0.0001; ns P≥0.05 using the Wilcoxon matched-pairs signed rank test (assessed at the 5% level of significance). Correlation (D) between fibrinolytic potential (FP) and clinical outcome after IPFT with LTI-01 (n=8; r=-0.79; p<0.05 by Spearman rank correlation). FP was determined in samples of PF collected prior to the IPFT as previously described (21, 22) . The values of % of changes in relative pleural density on CXR prior to (E) and after (F)
IPFT with LTI-01 were calculated as previously described (5) . The solid line represents the best fit of a linear equation to the data; with the % of relative changes in X-ray pleural density area (Table 3) . 
